Document is current
Any future updates will be listed below
-
Authors
Tanner, L. http://orcid.org/0000-0003-0626-9820
Single, A. B.
Bhongir, R. K. V. http://orcid.org/0000-0001-6648-1781
Heusel, M. http://orcid.org/0000-0002-8506-530X
Mohanty, T. http://orcid.org/0000-0003-4593-9612
Karlsson, C. A. Q.
Pan, L. http://orcid.org/0000-0003-2324-2144
Clausson, C-M.
Bergwik, J.
Wang, K.
Andersson, C. K.
Oommen, R. M.
Erjefält, J. S.
Malmström, J. http://orcid.org/0000-0002-2889-7169
Wallner, O.
Boldogh, I.
Helleday, T. http://orcid.org/0000-0002-7384-092X
Kalderén, C.
Egesten, A. http://orcid.org/0000-0001-5269-3433
- License Information
-
More Information
Article History
Received: 25 October 2021
Accepted: 26 January 2023
First Online: 6 February 2023
Competing interests
: T.H. is listed as inventor on a provisional U.S. patent application no. 62/636983, covering OGG1 inhibitors. The patent is fully owned by a nonprofit public foundation, the Helleday Foundation, and T.H. is a member of the foundation board developing OGG1 inhibitors toward the clinic. An inventor reward scheme is under discussion. The remaining authors declare no other competing interests.
